ESR1 and breast carcinoma: Since PMID16505416Sig822 was generated as an ER-responsive signature and only provided additional prognostic value in the tamoxifen-treated setting, we decided to evaluate the predictive value of the remaining two prognostic signatures to predict chemotherapy outcomes and drug sensitivity in breast cancer patients.